Biopharmaceutical CMO Market Report 2026

Biopharmaceutical CMO Market Overview

• Biopharmaceutical CMO market size has reached to $28.02 billion in 2025 • Expected to grow to $54.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.2% • Growth Driver: Biopharmaceutical Cmo Market And Chronic Disease Burden • Market Trend: Biopharmaceutical Cmo Market Consolidation Trends • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biopharmaceutical CMO Market?

Biopharmaceutical CMO is a business that provides manufacturing services, with the capacity to produce small quantities for preclinical research and development and more significant numbers needed for clinical trials and commercialization. The biopharmaceutical CMO assists in lowering overall operational risk and time to market. The main types of biopharmaceutical CMO products includes biologics and biosimilars. The biologics are used to produce a wide range of products derived from human, animal, or microbial sources as biologic medications. Biologics are substance made from living things or contains some components of them. Vaccines, blood, blood components, cells, allergies, genes, tissues, and recombinant proteins are some of the biologic medications. The biopharmaceutical CMO products comes from various sources including mammalian and non-mammalian. The biopharmaceutical CMO services includes manufacturing, fill and finish operations, analytical and qc studies, and packaging.

What Is The Biopharmaceutical CMO Market Growth Forecast?

The biopharmaceutical cmo market size is expected to see rapid growth in the next few years. It will grow to $54.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing investments in advanced biologics, rising demand for rapid scale-up manufacturing, expansion of personalized therapies, growing adoption of continuous bioprocessing, increasing focus on risk-sharing manufacturing models. Major trends in the forecast period include increasing outsourcing of biologics manufacturing, rising demand for biosimilar production services, growing use of single-use bioprocessing systems, expansion of cell and gene therapy manufacturing, enhanced focus on end-to-end cmo capabilities.

Global Biopharmaceutical CMO Market Segmentation

1) By Product: Biologics, Biosimilars 2) By Source: Mammalian, Non-Mammalian 3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging Subsegments: 1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies 2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

What Is The Driver Of The Biopharmaceutical CMO Market?

The increasing burden of chronic diseases is expected to propel the growth of the biopharmaceutical CMO market going forward. Chronic diseases are long-term health conditions that persist over a person's lifetime, often progressing slowly and requiring ongoing medical management. Biopharmaceutical CMOs can enhance the fight against chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards, thereby increasing accessibility and affordability of life-saving medications. For instance, in January 2024, according to World Health Organization, a Switzerland-based intergovernmental organization, reported that the burden of noncommunicable diseases primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes continues to increase, they kill 41 million people every year, representing 74% of all deaths and the vast majority of premature mortality worldwide, with the greatest impact in low- and middle-income countries. Therefore, increasing burden of chronic diseases drives the biopharmaceutical CMOs industry.

Key Players In The Global Biopharmaceutical CMO Market

Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

Global Biopharmaceutical CMO Market Trends and Insights

Major companies operating in the biopharmaceutical CMO market are adopting strategic partnerships approach to develop innovative biopharmaceutical products. Strategic partnerships help biopharmaceutical CMO companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach, and accelerating commercialization, ultimately driving innovation and growth in the biopharmaceutical CMO industry. For instance, in May 2024, BioConnection, a Netherlands-based contract manufacturing company, partnered with AGC Biologics, a US-based contract development and manufacturing company. With this partnership, they aim to deliver a streamlined, comprehensive solution for biopharmaceutical development and manufacturing, expediting timelines and simplifying processes for drug developers.

What Are Latest Mergers And Acquisitions In The Biopharmaceutical CMO Market?

In May 2023, WACKER, a Germany-based chemical company, acquired ADL BioPharma for an undisclosed amount. The aim of the acquisition is to enhance WACKER biotechnology operations and increase fermentation capacities for sustainably produced food ingredients, supporting its future growth objectives. ADL BioPharma is a Spain-based contract manufacturing company that specializes in the development and production of premium fermentation products.

Regional Outlook

North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biopharmaceutical CMO Market?

The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biopharmaceutical CMO Market Report 2026?

The biopharmaceutical cmo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical cmo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.